[1]
Banerjee, A.; Chisti, C.; Banerjee, U.C. Streptokinase-a clinically useful thrombolytic agent. Biotechnol. Adv., 2004, 22, 287-307.
[2]
Collen, D. Coronary thrombolysis: Streptokinase or recombinant tissue-type plasminogen activator? Ann. Intern. Med., 1990, 112(7), 529-538.
[3]
Chauhan, S.; Meena, S. Pegylation - a surprising technology. Int. Pharmaceut. Sciencia, 2011, 1(2), 18-24.
[4]
Keramati, M.; Arabi Mianroodi, R.; Memarnejadian, A.; Mirzaie, A.; Sazvari, S.; Aslani, M.M.; Roohvand, F. Towards a superior streptokinase for fibrinolytic therapy of vascular thrombosis. Cardiovasc. Hematol. Agents Med. Chem., 2013, 11(3), 218-229.
[5]
Cardoso, C.D. Jr., Perobelli, R.F.; Xavier, B.; Maldaner, F.P.; da Silva, F.S.; Dalmora, S.L. Analysis of streptokinase by validated liquid chromatography methods and correlation with an in vitro bioassay. J. Sep. Sci., 2017, 40(2), 407-414.
[6]
Huish, S.; Thelwell, C.; Longstaff, C. Activity regulation by fibrinogen and fibrin of streptokinase from Streptococcus pyogenes. PLoS One, 2017, 12(1), e0170936.
[7]
Mukhametova, L.I.; Aisina, R.B.; Zakharyan, E.M.; Karakhanov, E.A.; Gershkovich, K.B.; Varfolomeyev, S.D. Thrombolytic and fibrinogenolytic properties of bioconjugate streptokinase-polyamidoamine dendrimers in vitro. Thromb. Res., 2017, 154, 50-52.
[8]
Yaghoobi, N.; Faridi, M.R.; Faramarzi, M.A.; Baharifar, H.; Amani, A. Preparation, optimization and activity evaluation of PLGA/streptokinase nanoparticles using electrospray. Adv. Pharm. Bull., 2017, 7(1), 131-139.
[9]
Azdaki, N.; Mohammadifard, M.; Ghasemian, M.R.; Saburi, A. Successful intravenous streptokinase therapy in refractory extensive deep vein thrombosis associated with inferior vena cava agenesis: A novel treatment for a rare case. Ann. Card. Anaesth., 2017, 20(2), 268-269.
[10]
Baruah, D.B.; Rajendra, N.D.; Chaudhari, M.R.; Kadam, S.S. Plasminogen activators: A comparison. Vascul. Pharmacol., 2006, 44, 1-9.
[11]
Cox, G.N.; Smith, D.J.; Carlson, S.J.; Bendele, A.M.; Chlipala, E.A.; Doherty, D.H. Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp. Hematol., 2004, 32(5), 441-449.
[12]
Doherty, D.H.; Rosendahl, M.S.; Smith, D.J.; Hughes, J.M.; Chlipala, E.A.; Cox, G.N. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjug. Chem., 2005, 16(5), 1291-1298.
[13]
Kumar, S.; Maheshwari, N.; Shani, G. Mutants of streptokinase and
their covalently modified forms. U.S. Patent 8,093,032 B2, 2012.
[14]
Parhami-seren, B.; Lynch, M.; Whites, H.D.; Reed, G.L. Mapping the antigenic regions of streptokinase in humans before and after streptokinase therapy. Mol. Immunol., 1995, 32(10), 111-124.
[15]
Rajagopalan, S.; Gonias, S.L.; Pizzo, S.V. A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. J. Clin. Invest., 1985, 75, 413-419.
[16]
Torrens, I.; Ojalvo, A.G.; Seralenam, A.; Hayes, O.; Fuente, J. A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunol. Lett., 1999, 70, 213-218.
[17]
Brucato, F.H.; Pizzo, S.V. Catabolism of streptokinase and polyethylene glycol-streptokinase: evidence for transport of intact forms through the biliary system in the mouse. Blood, 1990, 76, 73-79.
[18]
Lee, J.I.; Eisenberg, S.P.; Rosendahl, M.S.; Chlipala, E.A.; Brown, J.D.; Doherty, D.H.; Cox, G.N. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b. J. Interferon Cytokine Res., 2013, 33(12), 769-777.
[19]
Sawhney, P.; Katare, K.; Sahni, G. pegylation of truncated streptokinase leads to formulation of a useful drug with ameliorated attributes. PLoS One, 2016, 11(5), e0155831.
[20]
Sawhney, P.; Kumar, S.; Maheshwari, N.; Guleria, S.S.; Dhar, N.; Kashyap, R.; Sahni, G. Site-specific thiol-mediated pegylation of streptokinase leads to improved properties with clinical potential. Curr. Pharm. Des., 2016, 22(38), 5868-5878.
[21]
Koide, A.; Suzuki, S.; Kobayashi, S. Preparation of polyethylene glycol-modified streptokinase with disappearance of binding ability towards anti-serum and retention of activity. FEBS Lett., 1982, 143(1), 73-76.
[22]
Rosendahl, M.S.; Doherty, D.H.; Smith, D.J.; Carlson, S.J.; Chlipala, E.A.; Cox, G.N. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. Bioconjug. Chem., 2005, 16(1), 200-207.
[23]
Wang, X.; Lin, X.; Lay, J.A.; Tang, J.; Zhang, X.C. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science, 1998, 281, 1662-1665.
[24]
Sambrook, J.; Russell, D. Molecular cloning: a laboratory manual, 3rd ed; Cold Spring Harbor Laboratory Press: New York, 2001.
[25]
Arabi, R.; Roohvand, F.; Norouzian, D.; Sardari, S.; Aghasadeghi, M.; Khanahmad, H.; Memarnejadian, A.; Motevalli, F. A comparative study on the activity and antigenicity of truncated and full-length forms of streptokinase. Pol. J. Microbiol., 2011, 60, 243-251.
[26]
QIAGEN. The QIAexpressionist. A handbook for high-level expression and purification of 6xHis-tagged proteins, 3rd ed; Hilden: Germany, 2000.
[27]
Reed, G.L.; Houng, A.K.; Liu, L.; Parhami-Seren, B.; Matsueda, L.H.; Wang, S.; Hedstrom, L. A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. Proc. Natl. Acad. Sci., 1999, 96(16), 8879-8883.
[28]
Parhami-Seren, B.; Seaveya, M.; Krudysza, J.; Tsantili, P. Structural correlates of a functional streptokinase antigenic epitope: serine 138 is an essential residue for antibody binding. J. Immunol. Methods, 2003, 272, 93-105.
[29]
Reed, G.; Kussie, P.; Parhami-seren, B. A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments. J. Immunol., 1993, 150(10), 4407-4415.
[30]
Reed, G.L.; Kussie, P.; Parhami-Seren, B. A functional analysis of the antigenicity of streptokinase using monoclonal antibody mapping and recombinant streptokinase fragments. J. Immunol., 1993, 150(10), 4407-4415.
[31]
Coffey, J.A.; Jennings, K.R.; Dalton, H. New antigenic regions of streptokinase are identified by affinity directed mass spectrometry. Eur. J. Biochem., 2001, 268, 5215-5221.
